Sugi Predict

Sugi Predict / Compounds / SCHEMBL780412

SCHEMBL780412

SCHEMBL780412

Cc1cccc([C@@H](C)N)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 4/20 0.50
▸ AOC3 Q16853 1/20 0.44
▸ ACP3 P15309 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ ADRB1 P08588 1/20 0.39
▸ MIF P14174 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ ADRA1A P35348 1/20 0.39
▸ HTR2B P41595 1/20 0.39
▸ ADRB2 P07550 1/20 0.39
▸ EPHX1 P07099 1/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ TAAR1 Q96RJ0 1/20 0.39
▸ MAPT P10636 1/20 0.38
▸ HTR3E A5X5Y0 1/20 0.38
▸ HTR3B O95264 1/20 0.38
▸ HTR3A P46098 1/20 0.38
▸ HTR3D Q70Z44 1/20 0.38
▸ HTR3C Q8WXA8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3350656 1.00 ACHE (0.50) ACHEAOC3ACP3ALDH1A1MAPK1
SCHEMBL1238870 1.00 ACHE (0.50) ACHEAOC3ACP3ALDH1A1MAPK1
Hydrochloric Acid SCHEMBL2150146 0.98 ACHE (0.48) ACHEAOC3ACP3ALDH1A1MAPK1
Hydrochloric Acid SCHEMBL16322028 0.98 ACHE (0.48) ACHEAOC3ACP3ALDH1A1MAPK1
Hydrochloric Acid SCHEMBL5777749 0.98 ACHE (0.48) ACHEAOC3ACP3ALDH1A1MAPK1
SCHEMBL7872122 0.85 SLC6A2 (0.44) ALDH1A1ADRB2MAPT
SCHEMBL659099 0.85 ADRB2 (0.46) ALDH1A1ADRB1MIFHTR2AADRA1A
SCHEMBL3259002 0.83 ACHE (0.52) ACHEAOC3ACP3ALDH1A1MAPK1
SCHEMBL3254719 0.83 ACHE (0.52) ACHEAOC3ACP3ALDH1A1MAPK1
SCHEMBL12569050 0.83 ACHE (0.52) ACHEAOC3ACP3ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12565511-B2 SOS1 inhibitor containing phosphorus CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2026-03-03 — — US disclosed
CN-120058796-A Phosphorus-containing SOS1 inhibitors 正大天晴药业集团股份有限公司 2025-05-30 — — CN disclosed
CN-120058795-A Phosphorus-containing SOS1 inhibitors 正大天晴药业集团股份有限公司 2025-05-30 — — CN disclosed
CN-120058797-A Phosphorus-containing SOS1 inhibitors 正大天晴药业集团股份有限公司 2025-05-30 — — CN disclosed
US-20250145561-A1 4-SUBSTITUTED-PHENYL ACETAMIDES AND ARYLUREAS AS AGONISTS FOR THE ORPHAN RECEPTOR GPR88 RESEARCH TRIANGLE INSTITUTE (US) 2025-05-08 — — US disclosed
CN-115461342-B Phosphorus-containing SOS1 inhibitors 正大天晴药业集团股份有限公司 2025-02-21 — — CN disclosed
EP-4469431-A1 4-SUBSTITUTED-PHENYL ACETAMIDES AND ARYLUREAS AS AGONISTS FOR THE ORPHAN RECEPTOR GPR88 Research Triangle Institute (US) 2024-12-04 — — EP disclosed
CN-118541348-A 4-Substituted-phenylacetamides and aryl ureas as agonists of the orphan receptor GPR88 研究三角协会 2024-08-23 — — CN disclosed
US-12053473-B2 Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-08-06 — — US disclosed
US-20240254151-A1 SOS1 INHIBITOR CONTAINING PHOSPHORUS CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2024-08-01 — — US disclosed
US-8716473-B2 Substituted benzotriazines and quinoxalines as inhibitors of P7OS6 kinase SENTINEL ONCOLOGY LIMITED (GB) 2014-05-06 — — US disclosed
US-20120295943-A9 CYCLOALKYLAMINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-11-22 — — US disclosed
US-20120295943-A9 CYCLOALKYLAMINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-11-22 — — US disclosed
EP-2027083-B1 METHOD OF PREPARING CHIRAL CYCLIC BETA-AMINOCARBOXAMIDES BOEHRINGER INGELHEIM INT (DE) 2012-07-11 — — EP disclosed
US-20120122941-A1 CYCLOALKYLAMINE DERIVATIVES MARUMOTO SHINJI (JP) 2012-05-17 — — US disclosed
US-20120122941-A1 CYCLOALKYLAMINE DERIVATIVES MARUMOTO SHINJI (JP) 2012-05-17 — — US disclosed
US-20120071478-A1 SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE SENTINEL ONCOLOGY LIMITED (GB) 2012-03-22 — — US disclosed
US-8076330-B2 Dipeptidyl peptidase-IV inhibitors AMGEN INC. (US) 2011-12-13 — — US disclosed
US-20110112051-A1 Dipeptidyl Peptidase-IV Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2011-05-12 — — US disclosed
US-7462738-B2 Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2008-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295943-A9 CYCLOALKYLAMINE DERIVATIVES CASR, CALCR, CALCRL ACHE 4595/4885AOC3 1227/4885ACP3 833/4885
US-20120071478-A1 SUBSTITUTED BENZOTRIAZINES AND QUINOXALINES AS INHIBITORS OF P7OS6 KINASE CDK1, CDK2, CDK6 ACHE 4431/4885AOC3 1829/4885ACP3 3930/4885
US-12565511-B2 SOS1 inhibitor containing phosphorus SOST, SOS1, SOS2 ACHE 4672/4885AOC3 1562/4885ACP3 1660/4885
US-20120122941-A1 CYCLOALKYLAMINE DERIVATIVES CASR, CALCR, CALCRL ACHE 4595/4885AOC3 1227/4885ACP3 833/4885
US-20250145561-A1 4-SUBSTITUTED-PHENYL ACETAMIDES AND ARYLUREAS AS AGONISTS FOR THE ORPHAN RECEPTOR GPR88 GPR88, GPR84, GPR139 ACHE 884/4885AOC3 676/4885ACP3 3566/4885
US-12053473-B2 Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors SOS1, SOS2, SOST ACHE 4042/4885AOC3 3210/4885ACP3 3451/4885
US-20240254151-A1 SOS1 INHIBITOR CONTAINING PHOSPHORUS SOST, SOS1, PPM1F ACHE 4408/4885AOC3 4359/4885ACP3 556/4885
US-20110112051-A1 Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP7 ACHE 2107/4885AOC3 4042/4885ACP3 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.